Aged Garlic Extract

evidence score
supplement
Evidence Level A
AGEKyolicgarlic supplement+3 more

Aged Garlic Extract (AGE) is the most clinically studied form of garlic supplementation, produced by aging sliced garlic in ethanol for 20+ months. This process converts unstable allicin into stable, bioavailable organosulfur compounds — primarily S-allylcysteine (SAC) and S-allylmercaptocysteine (SAMC). AGE has the strongest evidence base of any garlic form for blood pressure reduction: a 2020 Cochrane-quality meta-analysis of 12 RCTs (Ried et al.) found AGE reduces systolic BP by 8-10 mmHg in hypertensive individuals, comparable to first-line antihypertensives. In TRT contexts, garlic extract is relevant because testosterone increases erythropoiesis and hematocrit — cardiovascular risk factors that AGE can partially offset via BP reduction, improved arterial compliance, and reduced coronary artery calcification. The 2016 Matsumoto trial demonstrated AGE reduced coronary plaque progression in metabolic syndrome patients. Also shows modest LDL reduction and immune support via NK cell activation.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

Multiple RCTs and meta-analyses; OTC supplement

Last Sync

Not synced yet

Last Reviewed

Not reviewed yet

Dosing

Typical
1200 mg
600 mgRange2400 mg
Frequencydaily (1-2 divided doses with meals)

Set height & weight in Settings to see your dose.

Pharmacology

Half-lifeS-allylcysteine: ~10 hours
OnsetBlood pressure effects within 2-4 weeks; lipid effects 8-12 weeks
DurationOngoing with daily dosing
Routes
oral

Evidence Score

0 studies indexed
Scoring Factors
Volume(24%)
Quality(24%)
Sample Size(12%)
Consistency(14%)
Replication(8%)
Recency(18%)
Evidence Levels
AScore ≥75 with at least 1 meta-analysis and 3+ RCTs
BScore ≥50 with at least 1 RCT or meta-analysis
CScore ≥25 — observational or animal evidence only
DScore <25 — very limited or preclinical data

Plain-English Snapshot

Aged Garlic Extract is currently categorized as a supplement compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

S-allylcysteine inhibits ACE and activates eNOS → vasodilation and BP reduction; polysulfides activate TRPA1/H2S signaling; organosulfur compounds reduce oxidative stress and inflammation

Practical Context

Strongest current signals

No indexed study summaries yet.

Compound Profile